Long-Term Risk of Gout in Living Kidney Donors
ClinicalTrials.gov Studies
Summary
A population-based, matched, retrospective cohort study (NCT07546643) has been registered to evaluate long-term gout risk among living kidney donors versus matched healthy nondonors using linked administrative healthcare databases from Ontario, Alberta, and British Columbia. Donors who donated between 1992 and 2024 will be identified and matched 1:10 to healthy nondonors, with the primary outcome being the first healthcare encounter with a gout diagnosis and secondary outcomes including dispensed prescriptions for allopurinol, colchicine, or febuxostat. The study aims to inform clinical guidelines and support decision-making among potential donors, recipients, and transplant clinicians.
“The primary outcome is the first health care encounter with a diagnosis of gout.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov registry entry documents a new observational study (NCT07546643) examining whether living kidney donors face a higher long-term risk of gout compared to matched healthy individuals who did not donate. The study will use linked administrative healthcare databases across three Canadian provinces (Ontario, Alberta, and British Columbia) covering donors from 1992 to 2024, with a 1:10 matched cohort design and both diagnostic and pharmaceutical secondary outcomes. Healthcare providers and transplant programs should be aware that study findings may inform future pre-donation counselling protocols and clinical guidelines regarding gout risk following kidney donation.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Long-Term Risk of Gout in Living Kidney Donors
Observational NCT07546643 Kind: OBSERVATIONAL Apr 23, 2026
Abstract
This population-based, matched, retrospective cohort study will evaluate the long-term risk of gout among living kidney donors compared with matched healthy nondonors, using linked administrative health care databases from Ontario, Alberta, and British Columbia. Living kidney donors who donated between 1992 and 2024 will be identified and matched 1:10 to a carefully selected population of healthy nondonors based on baseline characteristics. The primary outcome is the first health care encounter with a diagnosis of gout. Secondary outcomes include receipt of a dispensed prescription for the composite of allopurinol, colchicine, or febuxostat, and each medication separately. The findings will provide evidence to inform clinical guidelines, support informed decision-making among potential donors and recipients, and guide counselling by transplant clinicians.
Conditions: Living Kidney Donation, Living Kidney Donor, Gout, Gout and Hyperuricemia
Interventions: Living kidney donation
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.